SRRK
Closed
Scholar Rock Holding Corp
33.755
-1.665 (-4.70%)
Last Update: 01 Jul 2025 23:00:00
Yesterday: 35.42
Day's Range: 33.69 - 35.595
Send
sign up or login to leave a comment!
When Written:
8.04
Scholar Rock Holding Corp is a clinical-stage biopharmaceutical company that focuses on the discovery and development of innovative medicines to treat serious diseases in patients with unmet medical needs. The company is headquartered in Cambridge, Massachusetts, and was founded in 2012.
Scholar Rock's lead product candidate, SRK-015, is being developed for the treatment of spinal muscular atrophy (SMA), a rare and often fatal genetic disease that affects the muscles used for movement. SRK-015 is designed to selectively inhibit the activation of a protein called myostatin, which plays a key role in muscle growth and development.
In addition to SMA, Scholar Rock is also exploring the potential of its technology platform in other disease areas, including cancer, fibrosis, and immune-mediated diseases.
The company went public in 2018 and is traded on the NASDAQ under the ticker symbol SRRK. As of 2021, Scholar Rock has a market capitalization of over $1 billion.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
Scholar Rock's lead product candidate, SRK-015, is being developed for the treatment of spinal muscular atrophy (SMA), a rare and often fatal genetic disease that affects the muscles used for movement. SRK-015 is designed to selectively inhibit the activation of a protein called myostatin, which plays a key role in muscle growth and development.
In addition to SMA, Scholar Rock is also exploring the potential of its technology platform in other disease areas, including cancer, fibrosis, and immune-mediated diseases.
The company went public in 2018 and is traded on the NASDAQ under the ticker symbol SRRK. As of 2021, Scholar Rock has a market capitalization of over $1 billion.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
(0)
(0)
Send
sign up or login to leave a comment!!